H.C. Wainwright analyst Swayampakula Ramakanth maintained a Buy rating on AbSci (ABSI – Research Report) today and set a price target of $7.00.

H.C. Wainwright analyst Heiko Ihle raised the firm’s price target on DRDGold (DRD) to $17.25 from $13.25 and keeps a Buy rating on the shares.

Immunic Inc (IMUX) stock saw a modest uptick, ending the day at $0.95 which represents no change from the prior close of of $0.95. The stock opened at $0.98 and touched a low of $0.92 during the day, ...

H.C. Wainwright maintained a positive outlook on Axsome Therapeutics (NASDAQ:AXSM), reiterating a Buy stock rating with a ...

HC Wainwright reaffirmed their buy rating on shares of Anavex Life Sciences (NASDAQ:AVXL – Free Report) in a report issued on Tuesday morning,Benzinga reports. HC Wainwright currently has a $42.00 ...

HC Wainwright decreased their Q3 2025 EPS estimates for shares of Applied Digital in a research note issued to investors on ...

BTCS Inc. (Nasdaq: BTCS) (“BTCS” or the“Company”), a leader in blockchain infrastructure and technology, has announced its ...

On Tuesday, Ardelyx Inc (ARDX) stock saw a decline, ending the day at $4.91 which represents a decrease of $-0.10 or -2.00% from the prior close of $5.01. The stock opened at $5.05 and touched a low ...

Fintel reports that on January 17, 2025, HC Wainwright & Co. downgraded their outlook for CECO Environmental (NasdaqGS:CECO) ...

H.C. Wainwright initiated coverage of MetaVia (MTVA) with a Buy rating and $12 price target The company’s DA-1726 is a novel oxyntomodulin analogue designed as a dual agonist targeting glucagon ...

H.C. Wainwright raised the firm’s price target on Sana Biotechnology (SANA) to $11 from $8 and keeps a Buy rating on the shares. The firm increased its probability of sucess for SC451 to 15% ...

RAPT Therapeutics (NASDAQ:RAPT) shares rose on Thursday after H.C. Wainwright upgraded the immunology-focused biotech to Buy from Neutral based on the company's recent licensing deal with China's ...